QT prolongation with anticancer drugs: a multimodal issue - Authors' reply

Lancet Oncol. 2022 Dec;23(12):e523. doi: 10.1016/S1470-2045(22)00695-7.

Authors

Eline L Giraud¹, Nielka P van Erp¹, Elise J Smolders²

Affiliations

¹ Department of Clinical Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
² Department of Clinical Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands; Department of Clinical Pharmacy, Isala Hospital, Zwolle, Netherlands. Electronic address: elise.smolders@radboudumc.nl.

PMID: 36455572
DOI: 10.1016/S1470-2045(22)00695-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents* / adverse effects
Humans
Long QT Syndrome* / chemically induced
Long QT Syndrome* / diagnosis

Substances

Antineoplastic Agents